National Research (NASDAQ:NRC) Shares Gap Up to $34.36

National Research Co. (NASDAQ:NRC) shares gapped up prior to trading on Wednesday . The stock had previously closed at $34.36, but opened at $35.84. National Research shares last traded at $34.37, with a volume of 2,135 shares changing hands.

Analyst Upgrades and Downgrades

Separately, TheStreet lowered National Research from a “b-” rating to a “c+” rating in a report on Thursday, January 11th.

National Research Price Performance

The stock has a market cap of $783.95 million, a price-to-earnings ratio of 26.30 and a beta of 0.42. The stock has a fifty day simple moving average of $38.66 and a 200-day simple moving average of $40.20. The company has a current ratio of 0.67, a quick ratio of 0.67 and a debt-to-equity ratio of 0.60.

National Research (NASDAQ:NRC) last released its earnings results on Tuesday, February 13th. The company reported $0.36 earnings per share (EPS) for the quarter. The firm had revenue of $38.00 million for the quarter. National Research had a return on equity of 47.79% and a net margin of 20.84%.

National Research Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 29th were issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.46%. The ex-dividend date was Wednesday, March 27th. National Research’s payout ratio is presently 38.40%.

Institutional Trading of National Research

Several institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in shares of National Research by 2.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,656 shares of the company’s stock worth $360,000 after purchasing an additional 231 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of National Research by 1.4% during the 2nd quarter. Rhumbline Advisers now owns 19,331 shares of the company’s stock worth $841,000 after purchasing an additional 272 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of National Research by 4.2% during the 4th quarter. MetLife Investment Management LLC now owns 7,239 shares of the company’s stock worth $270,000 after purchasing an additional 292 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of National Research by 2.3% during the 4th quarter. Legal & General Group Plc now owns 13,522 shares of the company’s stock worth $535,000 after purchasing an additional 306 shares in the last quarter. Finally, Summit Global Investments boosted its stake in National Research by 3.8% in the 3rd quarter. Summit Global Investments now owns 8,452 shares of the company’s stock valued at $375,000 after buying an additional 310 shares in the last quarter. Institutional investors and hedge funds own 47.26% of the company’s stock.

National Research Company Profile

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.